Back

PCSK9 inhibitors and cardiovascular outcomes in AMI-BIRISK patients: a multicenter retrospective study

1 September 2025 (12:20 - 12:30)
Organised by: Logo
Congress Presentation Part of: Novel pharmacological approaches in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jiayi Ren

2nd Hospital of Tianjin Medical University, Tianjin (China)

5 More presentations in this session

Presentation thumbnail
Heart rate and cardiovascular outcomes with and without beta-blocker in post-mi patients: a pre-specified analysis of the ABYSS trial.
Associate Professor M. Zeitouni (Paris, FR)
Abstract Slides
Presentation thumbnail
Inhibition of fractalkine signalling reduces intramyocardial haemorrhage and left ventricular thrombus in patients with acute myocardial infarction by modulating immunothrombosis (The FRACTAL trial)
Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)
Abstract Slides
Presentation thumbnail
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
Mr V. Oliveira (Goiania, BR)
Abstract Slides
Presentation thumbnail
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
Professor C. Su (Taichung, TW)
Abstract Slides
Presentation thumbnail
Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients
Mr J. Yun (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Novel pharmacological approaches in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 12:20 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources